Core Insights - Mangoceuticals, Inc. has announced promising data regarding its proprietary antiviral compound MGX-0024, which shows potential in reducing respiratory disease impacts in poultry and providing early protection against highly pathogenic avian influenza (HPAI) H5N1 and other respiratory illnesses [1][5] Group 1: Field Trials and Results - In three independent commercial field trials in Tamil Nadu, India, approximately 29,000 broiler chickens received MGX-0024-infused drinking water, resulting in zero mortality attributed to respiratory pathogens, while historical data indicated expected mortality of around 50% [2][3] - The current results replicate earlier studies from May 2025, which also reported zero respiratory-related deaths in treated groups of 8,000–10,000 birds, demonstrating consistent efficacy across a larger population [3] - A controlled challenge study showed that MGX-0024 reduced mortality by up to 60% in chicks exposed to the H5N1 strain, with a significant extension in mean time to death [4] Group 2: Product and Market Positioning - MGX-0024 is a GRAS-classified formulation of select polyphenols and zinc, administered through standard farm drinking-water systems, offering a non-vaccine, non-antibiotic approach to managing respiratory diseases in poultry [5] - The company is scaling production and refining logistics while engaging in regulatory discussions in key markets, aligning with global trends toward reduced antibiotic use in poultry production [6] - Further multi-farm studies in India are planned, along with grant opportunities through USDA and other international equivalents, indicating a proactive approach to market expansion [6]